EP3310438A4 - Méthode de traitement de la glomérulosclérose segmentaire focale primaire - Google Patents

Méthode de traitement de la glomérulosclérose segmentaire focale primaire Download PDF

Info

Publication number: EP3310438A4
Authority: EP; European Patent Office
Prior art keywords: focal segmental; segmental glomerulosclerosis; treating primary; primary focal; treating
Prior art date: 2015-06-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16812482.4A

Other languages

German (de)

English (en)

Other versions

EP3310438A1 (fr

Inventor

Steven R. Ledbetter

Sara ENGSTRAND

Patrick Finn

Julie Lin

Robert John POMPONIO

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genzyme Corp

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-19

Filing date

2016-06-17

Publication date

2018-11-21

2016-06-17 Application filed by Genzyme Corp filed Critical Genzyme Corp

2018-04-25 Publication of EP3310438A1 publication Critical patent/EP3310438A1/fr

2018-11-21 Publication of EP3310438A4 publication Critical patent/EP3310438A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

EP16812482.4A 2015-06-19 2016-06-17 Méthode de traitement de la glomérulosclérose segmentaire focale primaire Withdrawn EP3310438A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562182102P	2015-06-19	2015-06-19
PCT/US2016/037963 WO2016205581A1 (fr)	2015-06-19	2016-06-17	Méthode de traitement de la glomérulosclérose segmentaire focale primaire

Publications (2)

Publication Number	Publication Date
EP3310438A1 EP3310438A1 (fr)	2018-04-25
EP3310438A4 true EP3310438A4 (fr)	2018-11-21

Family

ID=57546326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16812482.4A Withdrawn EP3310438A4 (fr)	2015-06-19	2016-06-17	Méthode de traitement de la glomérulosclérose segmentaire focale primaire

Country Status (13)

Country	Link
US (1)	US20190062416A1 (fr)
EP (1)	EP3310438A4 (fr)
JP (1)	JP2018517721A (fr)
KR (1)	KR20180019125A (fr)
CN (1)	CN108290054A (fr)
AU (1)	AU2016280832A1 (fr)
CA (1)	CA2989629A1 (fr)
IL (1)	IL256321A (fr)
MX (1)	MX2017016533A (fr)
RU (1)	RU2018101865A (fr)
TW (1)	TW201718010A (fr)
WO (1)	WO2016205581A1 (fr)
ZA (1)	ZA201708305B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20250153881A (ko) *	2018-05-22	2025-10-27	아이오니스 파마수티컬즈, 인코포레이티드	Apol1 발현의 조절인자
JP2025503737A (ja)	2022-01-18	2025-02-04	メイズセラピューティクス，インコーポレイテッド	Ａｐｏｌ１阻害剤及び使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006086469A2 (fr) *	2005-02-08	2006-08-17	Genzyme Corporation	Anticorps anti-tgf-beta
US20120003644A1 (en) *	2010-06-07	2012-01-05	Rappaport Family Institute For Research In The Medical Sciences	Methods and kits for determining predisposition to develop kidney diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005097832A2 (fr) *	2004-03-31	2005-10-20	Genentech, Inc.	Anticorps anti-tgf-$g(b) humanises
WO2012013980A1 (fr) *	2010-07-30	2012-02-02	Arecor Limited	Compositions aqueuses stabilisées d'anticorps

2016
- 2016-06-16 TW TW105118870A patent/TW201718010A/zh unknown
- 2016-06-17 WO PCT/US2016/037963 patent/WO2016205581A1/fr not_active Ceased
- 2016-06-17 AU AU2016280832A patent/AU2016280832A1/en not_active Abandoned
- 2016-06-17 US US15/737,069 patent/US20190062416A1/en not_active Abandoned
- 2016-06-17 JP JP2017564571A patent/JP2018517721A/ja active Pending
- 2016-06-17 CN CN201680047657.0A patent/CN108290054A/zh active Pending
- 2016-06-17 CA CA2989629A patent/CA2989629A1/fr not_active Abandoned
- 2016-06-17 MX MX2017016533A patent/MX2017016533A/es unknown
- 2016-06-17 KR KR1020177037355A patent/KR20180019125A/ko not_active Withdrawn
- 2016-06-17 RU RU2018101865A patent/RU2018101865A/ru not_active Application Discontinuation
- 2016-06-17 EP EP16812482.4A patent/EP3310438A4/fr not_active Withdrawn
2017
- 2017-12-07 ZA ZA2017/08305A patent/ZA201708305B/en unknown
- 2017-12-14 IL IL256321A patent/IL256321A/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006086469A2 (fr) *	2005-02-08	2006-08-17	Genzyme Corporation	Anticorps anti-tgf-beta
US20120003644A1 (en) *	2010-06-07	2012-01-05	Rappaport Family Institute For Research In The Medical Sciences	Methods and kits for determining predisposition to develop kidney diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AVI Z. ROSENBERG ET AL: "Focal Segmental Glomerulosclerosis", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 12, no. 3, 27 February 2017 (2017-02-27), pages 502 - 517, XP055513283, ISSN: 1555-9041, DOI: 10.2215/CJN.05960616 *
FLAVIO VINCENTI ET AL: "A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis", KIDNEY INTERNATIONAL REPORTS, vol. 2, no. 5, 1 September 2017 (2017-09-01), pages 800 - 810, XP055513278, ISSN: 2468-0249, DOI: 10.1016/j.ekir.2017.03.011 *
HOWARD TRACHTMAN ET AL: "A phase 1, single-dose study of fresolimumab, an anti-TGF-[beta] antibody, in treatment-resistant primary focal segmental glomerulosclerosis", KIDNEY INTERNATIONAL, vol. 79, no. 11, 1 June 2011 (2011-06-01), LONDON, GB, pages 1236 - 1243, XP055513276, ISSN: 0085-2538, DOI: 10.1038/ki.2011.33 *
PHYLLIS AUGUST: "TRANSFORMING GROWTH FACTOR BETA AND EXCESS BURDEN OF RENAL DISEASE", TRANSACTIONS OF THE AMERICAN CLINICAL AND CLIMATOLOGICAL ASSOCIATION, 1 January 2009 (2009-01-01), pages 61 - 72, XP055513487, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744541/pdf/tacca120000061.pdf> [retrieved on 20181009] *
See also references of WO2016205581A1 *

Also Published As

Publication number	Publication date
CN108290054A (zh)	2018-07-17
JP2018517721A (ja)	2018-07-05
AU2016280832A1 (en)	2018-01-18
ZA201708305B (en)	2018-11-28
TW201718010A (zh)	2017-06-01
US20190062416A1 (en)	2019-02-28
KR20180019125A (ko)	2018-02-23
WO2016205581A1 (fr)	2016-12-22
RU2018101865A (ru)	2019-07-22
EP3310438A1 (fr)	2018-04-25
IL256321A (en)	2018-02-28
CA2989629A1 (fr)	2016-12-22
MX2017016533A (es)	2018-05-28

Publication	Publication Date	Title
IL266751A (en)	2019-07-31	A method for the treatment of focal segmental tuberous sclerosis
EP3500289A4 (fr)	2020-05-06	Procédés de traitement de la trachéobronchomalacie
EP3307286A4 (fr)	2018-12-26	Procédé de traitement
EP3351296A4 (fr)	2019-05-22	Procédé de traitement de gaz
EP3253401A4 (fr)	2018-11-21	Méthode de traitement de maladies
GB2558789B (en)	2019-01-09	Method of authentication
GB201604627D0 (en)	2016-05-04	Improved method of FT-IMS
EP3236963A4 (fr)	2018-08-08	Procédé de traitement
EP3220952A4 (fr)	2018-03-28	Méthode de traitement ou de prévention d'un accident vasculaire cérébral
EP3491129A4 (fr)	2020-01-22	Procédés de traitement de l'osmidrose
EP3226864A4 (fr)	2018-04-04	Procédés de traitement de la fibrose
IL256321A (en)	2018-02-28	Method of treating primary focal segmental glomerulosclerosis
SG11201706885RA (en)	2017-09-28	Novel treatment method
EP3131904A4 (fr)	2017-11-22	Méthodes de traitement de l'hypersomnie
EP3148523A4 (fr)	2018-01-24	Procédé d'inhibition ou de traitement de la fibrose
PL2937084T3 (pl)	2017-05-31	Sposób leczenia hipercholesterolemii
HK40015333A (en)	2020-08-28	Method of treating focal segmental glomerulosclerosis
EP3246432A4 (fr)	2018-08-29	Procédé de traitement de pièces
HK40007068A (zh)	2020-05-29	治疗方法
AU2016904966A0 (en)	2016-12-15	Method of treatment
GB201417170D0 (en)	2014-11-12	Focusing method
AU2015901388A0 (en)	2015-04-30	Method of authentication
AU2015900498A0 (en)	2015-03-05	Method of treatment
AU2016902980A0 (en)	2016-08-11	Method of Treatment
AU2016902594A0 (en)	2016-07-14	Method of Treatment

Legal Events

Date	Code	Title	Description
2018-03-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-04-25	17P	Request for examination filed	Effective date: 20180117
2018-04-25	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-04-25	AX	Request for extension of the european patent	Extension state: BA ME
2018-07-18	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: GENZYME CORPORATION
2018-09-26	DAV	Request for validation of the european patent (deleted)
2018-09-26	DAX	Request for extension of the european patent (deleted)
2018-11-21	A4	Supplementary search report drawn up and despatched	Effective date: 20181018
2018-11-21	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 13/12 20060101AFI20181012BHEP Ipc: C07K 14/775 20060101ALI20181012BHEP Ipc: C07K 16/22 20060101ALI20181012BHEP Ipc: A61K 39/395 20060101ALI20181012BHEP
2019-08-07	17Q	First examination report despatched	Effective date: 20190704
2021-01-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2021-02-17	18D	Application deemed to be withdrawn	Effective date: 20200908